|
Contact:
| David K. Waldman/John W. Heilshorn |
The Quigley Corporation |
| Lippert Heilshorn & Associates |
Carl Fonash |
| (212) 838-3777 |
Shareholder Relations |
| dwaldman@lhai.com |
(267) 880-1111 |
The Quigley Corporation Reports 26.5% Increase in Revenue for the Third Quarter
DOYLESTOWN, PA. - October 28, 2003 - The Quigley Corporation (Nasdaq: QGLY) today reported
revenue of $9.9 million for the quarter ended September 30, 2003, a 26.5% increase over the $7.8 million
reported for the same period in 2002. For the first nine months of 2003, revenue was $25.1 million, a
39.3% increase over the $18.0 million in the first nine months of 2002.
The increase in the 2003 revenue for the third quarter reflects a 22.9% increase in the company's Health
and Wellness segment and a 30.9% increase in the Cold Remedy segment. The increase in the 2003
revenue for the nine months reflects a 47.8% increase in the company's Health and Wellness segment and
a 27.2% increase in the Cold Remedy segment. The Company's Health and Wellness revenues have
increased as its distribution continues to expand and Cold Remedy revenues have increased from the
benefits of continued ongoing strategic advertising, marketing initiatives and new products.
Guy J. Quigley, Chairman, President and Chief Executive Officer stated, "During the quarter, we
announced several developments in our Ethical Pharmaceutical segment. Firstly, Quigley Pharma's
formulation, which has already been shown to reduce the impact of influenza in both in-vivo and invitro
studies, is now to be tested against the SARS virus. Additionally, a preliminary study on our patent-
pending topical composition QR-337, indicated that skin conditions, such as dryness, redness, flaking,
scaling and cracking were observed to improve. The positive preliminary results exceeded those which
could be considered cosmetic and therefore indicate that the use of this new composition should be
studied as a potential treatment for skin disorders. We are now preparing an IND for submission to the
Food and Drug Administration to obtain permission to study and develop the formula as a prescription
drug, and as a potential treatment for psoriasis and other skin disorders. Lastly, we received two patents
for our compound QR-334, a new formulation currently being tested in clinical trials to relieve Sialorrhea,
excess secretions of the salivary glands."
Mr. Quigley continued, "We grew both our Cold Remedy and Health and Wellness segments, which has
contributed to funding our research and development in the Ethical Pharmaceutical segment. During the
quarter, we began shipping our new Kidz-EEZETM Sore Throat Pops and Cold-EEZEŽ Cold Remedy
Nasal Spray to retailers."
Income from continuing operations for the third quarter of 2003 was $134,000 or $0.01 per share,
compared to a loss from continuing operations of $289,000, or ($0.03) per share, for the same period last
year. Net income for the third quarter ended September 30, 2003 was $134,000 or $0.01 per share,
compared to a net loss of $500,000, or ($0.05) per share, in 2002.
Loss from continuing operations for the first nine months of 2003 was $1.8 million, or ($0.16) per share,
compared to a loss from continuing operations of $3.4 million, or ($0.31) per share, for the same period
last year. Net loss for the first nine months of 2003 was $1.9 million, or ($0.16) per share, compared to a
net loss of $3.7 million or ($0.34) per share in 2002.
Income (loss) from continuing operations for the quarter and nine months ended September 30, 2003
continues to improve, as compared with 2002, because the increases in consolidated revenues continue to
contribute comparable increases in gross profits, which were partially offset by increases in marketing,
administrative, and research and development costs.
No tax benefits to reduce losses are provided for the quarter and nine months ended September 30, 2003
and 2002, since the Company is in a net operating loss carry-forward position, which began in the fourth
quarter of 1999, from the cumulative effect of deductions attributed to options, warrants and unrestricted
stock from previous years' taxable income.
In January 2003, the Company completed the sale of its 60% equity interest in Caribbean Pacific Natural
Products, Inc. to Suncoast Naturals, Inc. by exchanging its 60% controlling interest in Caribbean Pacific
Natural Products, Inc. for 750,000 Shares of Common Stock and 100,000 Shares of Redeemable Preferred
Stock of Suncoast Naturals, Inc. The results of operations of Caribbean Pacific Natural Products, Inc. are
reflected as discontinued operations of the company for the periods presented. Net loss for the quarter
and nine months ended September 30, 2003 includes zero and $54,000, respectively and net loss for the
quarter and nine months ended September 30, 2002 includes $211,000 and $293,000, respectively
associated with discontinued operations of Caribbean Pacific Natural Products, Inc.
The Quigley Corporation makes no representation that the US Food and Drug Administration or any other
regulatory agency will grant an IND or take any other action to allow the QR formulation to be studied or
marketed. Furthermore, no claim is made that the potential medicine discussed here is safe, effective, or
approved by the Food and Drug Administration.
The Quigley Corporation (Nasdaq: QGLY, http://www.Quigleyco.com) is a leading developer and
marketer of diversified health products including the Cold-Eeze® family of patented zinc gluconate
glycine (ZIGGTM) lozenges and sugar free tablets. Cold-Eeze is the only (ZIGGTM) lozenge proven in two
double-blind studies to reduce the duration of the common cold from 7.6 to 4.4 days or by 42%. In
addition to Over-The-Counter (OTC) products, the company has formed Quigley Pharma Inc.
(http://www.QuigleyPharma.com ), a wholly owned ethical pharmaceutical subsidiary, to introduce a line
of naturally-derived patented prescription drugs. The Quigley Corporation's customers include leading
national wholesalers and distributors, as well as independent and chain food, drug and mass merchandise
stores and pharmacies.
Certain statements in this press release are "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995 and involve known and unknown risk, uncertainties and
other factors that may cause the company's actual performance or achievements to be materially different
from the results, performance or achievements expressed or implied by the forward-looking statement.
Factors that impact such forward-looking statements include, among others, changes in worldwide
general economic conditions, changes in interest rates, government regulations, and worldwide
competition
(Tables Follow)
Consolidated Statements of Operations (Unaudited)
The following represents condensed financial data (in thousands) except income
(loss) from continuing operations per share and diluted net loss per share and
weighted average shares outstanding for the periods presented:
Three-Months Three-Months Nine-Months Nine-Months
Ended Ended Ended Ended
Sept 30, 2003 Sept 30, 2002 Sept 30, 2003 Sept 30, 2002
Sales:
Sales 10,574 8,548 26,351 18,994
Co-operative advertising 662 714 1,243 1,122
Net Sales 9,912 7,834 25,108 17,872
Licensing fees - - - 149
Gross profit 4,488 3,111 10,948 7,177
Sales & marketing expenses 1,096 789 3,439 2,518
Administrative expenses 2,047 1,987 6,801 6,238
Research & development 1,230 666 2,599 1,897
Income taxes (Benefit) - - - -
Income (loss) from:
Continuing operations 134 (289) (1,813) (3,358)
Discontinued operations - (211) (54) (293)
Net income (loss) 134 (500) (1,867) (3,651)
Diluted income (loss) per share:
Continuing operations $0.01 ($0.03) ($0.16) ($0.31)
Discontinued operations - ($0.02) - ($0.03)
Net income (loss) $0.01 ($0.05) ($0.16) ($0.34)
Diluted weighted average common shares outstanding:
14,397,286 10,964,597 11,464,105 10,870,393
Consolidated Balance Sheets (Unaudited)
The following represents condensed financial data (in thousands) at September 30, 2003 and December 31, 2002:
2003 2002
($) ($)
Cash & cash equivalents 10,647 12,897
Accounts receivable, net 4,600 4,188
Inventory 4,526 4,527
Total current assets 20,490 22,476
Total assets 22,999 24,935
Total current liabilities 6,428 6,512
Total stockholders' equity 16,571 18,423
|
 |
